Nicholas S Rebold

9PUBLICATIONS
37CO-AUTHORS
Medical mycologyPharmacogenomicsMedical bacteriologyDental therapeutics, pharmacology and toxicologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 11, 2025
Real-World Applications of Imipenem-Cilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study.

Kaylee E Caniff, Nicholas Rebold, Xhilda Xhemali

|Mar 24, 2025
Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence.

Josiah Moore, Ndidi Iheme, Nicholas S Rebold

|Jan 25, 2024
Updates in pulmonary drug-resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM.

Dana J Holger, Ali Althubyani, Taylor Morrisette

|Mar 27, 2023
High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production.

Ashlan J Kunz Coyne, Amer El Ghali, Kristen Lucas

|Feb 02, 2023
Oral stepdown in Gram-positive bloodstream infections: A step in the right direction.

Kaylee E Caniff, Nicholas Rebold, Michael J Rybak

|Jan 09, 2023
Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure.

Nicholas Rebold, Abdalhamid M Lagnf, Sara Alosaimy

Pageof 2

Frequent Collaborators

6 joint publications

Michael J Rybak

4 joint publications

Ashlan J Kunz Coyne

3 joint publications

Dana J Holger

2 joint publications

Taylor Morrisette